← Leaderboards
Darcy Krueger
Boston Children'S Hospital
$10,517,407
Attributed
$18,824,207
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,560,541 · 4
FDA$3,263,666 · 1
By mechanism
U01$13,349,935 · 1
R01$3,263,666 · 1
U54$2,210,606 · 3
Top collaborators
- Mustafa None Sahin7 shared
- Martina Bebin3 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Charles Alexander Nelson$51,962,137
- Helen B. Tager-Flusberg$19,144,713
- Kimberly Wiltrout$153,972
- Michela Fagiolini$5,717,278
- Annapurna Poduri$4,100,888
Others in their field
Top investigators on “Rare Diseases”
- Richard A Gibbs · Baylor College Of Medicine$172,164,288
- Peter C Adamson · National Childhood Cancer Foundation$156,659,650
- James D Crapo · University Of Colorado Denver$75,971,906
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Michael A Province · Washington University$68,490,372
- Jeffrey P Krischer · University Of South Florida$63,824,555
Research focus
Rare DiseasesClinical TreatmentMolecularProspectiveFutureChildElectroencephalographyAutism Spectrum DisorderNatural HistoryBiological MarkersLifeSignal PathwayMutationInfantBehavioralEpilepsyLongevityPathway InteractionsClinical PhenotypeDesignImageBaseTuberous SclerosisTuberous Sclerosis Protein Complex
Grant awards (16)
Sirolimus TSC Epilepsy Prevention Study (STEPS) IND#145820 11/8/2019$650,881
R01 · FY2025 · FD · contact PI
Clinical Trial Readiness for the Evaluation and Treatment of Neuropsychiatric Manifestations in Tuberous Sclerosis Complex$331,018
U54 · FY2025 · NS · contact PI
Developing Biomarkers and Treatments for ASD and ID in Tuberous Sclerosis Complex$334,504
U54 · FY2023 · NS · contact PI
Sirolimus TSC Epilepsy Prevention Study (STEPS) IND#145820 11/8/2019$1,256,905
R01 · FY2022 · FD · contact PI
Developing Biomarkers and Treatments for ASD and ID in Tuberous Sclerosis Complex$328,460
U54 · FY2022 · NS · contact PI
Sirolimus TSC Epilepsy Prevention Study (STEPS) IND#145820 11/8/2019$1,355,880
R01 · FY2021 · FD · contact PI
Developing Biomarkers and Treatments for ASD and ID in Tuberous Sclerosis Complex$362,339
U54 · FY2021 · NS · contact PI
Developing Biomarkers and Treatments for ASD and ID in Tuberous Sclerosis Complex$368,891
U54 · FY2020 · NS · contact PI
Developing Biomarkers and Treatments for ASD and ID in Tuberous Sclerosis Complex$485,394
U54 · FY2019 · NS · contact PI
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$500,000
U01 · FY2018 · NS
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$500,000
U01 · FY2017 · NS
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$2,271,003
U01 · FY2016 · NS
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$1,360,955
U01 · FY2015 · NS
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$3,463,622
U01 · FY2014 · NS
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$2,604,574
U01 · FY2013 · NS
Early Biomarkers of Autism Spectrum Disorders in infants with Tuberous Sclerosis$2,649,781
U01 · FY2012 · NS